Table 2.
Multivariate Cox proportional hazards analysis.
| Variable | PFS |
OS |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age (≥65 years versus <65 years) | 0.79(0.28–2.25) | 0.658 | 0.16(0.03–0.76) | 0.021* |
| Gastroesophageal junction involvement (yes versus no) | 0.52(0.15–1.73) | 0.283 | 1.39(0.34–5.69) | 0.647 |
| Differentiation (poor versus well/moderate) | 0.45(0.12–1.66) | 0.231 | 1.69(0.29–9.7) | 0.556 |
| Lauren (diffuse versus intestinal/mixed) | 0.91(0.21–3.98) | 0.9 | 4.49(0.74–27.31) | 0.103 |
| HER2 status (positive versus negative) | 0.26(0.07–0.92) | 0.037* | 0.58(0.09–3.64) | 0.561 |
| Liver or lung involvement (yes versus no) | 0.72(0.2–2.57) | 0.617 | 2.34(0.45–12.07) | 0.311 |
| Baseline mTBI (≥1% versus <1%) | 13.75(2.69–70.24) | 0.002* | 8.19(0.83–80.95) | 0.072 |
Abbreviations: HER2, human epidermal growth factor receptor-2; mTBI, molecular tumor burden index; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
*
p ≤ 0.05